CytoSorbents reschedules earnings call to March 31; reaffirms Q4 product revenue $9.0-$9.2M (22-25% growth)

Cytosorbents Corp

Earnings call rescheduled to March 31, 2025 at 4:30 PM ET; annual audit still in progress.
Q4 product revenue expected $9.0-$9.2M (+22-25% YoY); full-year product revenue $35.4-$35.6M (+14% YoY).
Q4 product gross margin ~70%, vs 61% prior quarter and 72% prior year.
Pro-forma cash balance at Dec 31, 2024 ~$17.0M (unrestricted $15.5M); net Q4 cash burn ~$2.5M.
DrugSorb-ATR marketing applications under FDA and Health Canada review; regulatory decisions expected in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.